Product Images Tamsulosin Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Tamsulosin Hydrochloride NDC 43063-725 by Pd-rx Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

43063725 Label - 43063725

43063725 Label - 43063725

This is a label for a medication called Tamsulosin. Each bottle contains 90 capsules with 0.4mg per capsule. It has lot numbers and an expiration date of 12/2023. The label provides directions to take the medication by mouth, 1 capsule, multiple times a day. In case of side effects, patients are advised to call their doctor or report it to the FDA. There is additional text on the label that is unreadable due to errors.*

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) - tamsulosin fig1

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) - tamsulosin fig1

The text appears to be a figure caption or description for a graph showing the mean plasma concentration of tamsulosin hydrochloride at different time points after a single dose of 0.4 mg under fasted and fed conditions. However, the figure itself and more context is needed to provide a more complete description.*

Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1 - tamsulosin fig2

Figure 2A	Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1 - tamsulosin fig2

Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2 - tamsulosin fig3

Figure 2B	Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2 - tamsulosin fig3

This is a figure showing the mean change from baseline in total AUA symptom score (ranging from 0 to 35) for different treatments in Study 2. The treatments include O-O-0.08mg LNt, 0.4mg, and placebo. The figure also includes the duration of treatment in weeks. No further information is provided.*

Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1 - tamsulosin fig4

Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1 - tamsulosin fig4

This is a figure (Figure 3A) displaying the mean increase in peak urine flow rate in L/Sec for study 1. The x-axis represents the duration of treatment in weeks, while the y-axis represents the mean change in mL/sec in peak urine flow rate. The treatment groups are represented by symbols on the graph: 25 -O—O-—0-08mg, -A-=A=2x 0.4mg, and FPlacebo. There are also numerical values for the mean change in peak urine flow rate in mL/sec for each of the treatment groups at different time points (7, 10, 13, and LOGF [not sure what this means]). The number of people in each treatment group is also listed in parentheses next to the time points.*

Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2 - tamsulosin fig5

Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2 - tamsulosin fig5

This text is a figure caption showing the mean increase in peak urine flow rate in Study 2 over the course of treatment in weeks. Specific values are not available in the text.*

Chemical Structure - tamsulosin str

Chemical Structure - tamsulosin str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.